Skip to main content

Advertisement

Table 1 Patient characteristics

From: Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial

  Placebo (n = 85) Pregabalin (n = 82)
Male, n (%) 45 (52.9) 58 (70.7)
Race, n (%)   
   White 61 (71.8) 62 (75.6)
   Black 12 (14.1) 9 (11.0)
   Hispanic 12 (14.1) 9 (11.0)
   Other 0 2 (2.4)
Age, years   
   Mean (SD) 58.3 (10.9) 58.2 (9.6)
   Median 60 59.5
   Range (min-max) 32–86 31–79
Body Mass Index, (kg/m2)   
   Mean (SD) 35.8 (8.4) 36.6 (8.3)
   Range (min-max) 21.7–61.9 23.5–60.2
Weight, kg   
   Mean (SD) 105 (23) 107 (24)
   Median 104 102
   Range (min-max) 59–174 61–182
Diabetes type, n (%)   
   Type 1 9 (11) 4 (5)
   Type 2 76 (89) 78 (95)
Duration of diabetes, years   
   Mean (SD) 10.3 (8.6) 10.3 (8.2)
   Median 7.5 8.8
   Range (min-max) 0.3–42.2 0.6–42.8
Duration of painful DPN, years   
   Mean (SD) 4.4 (3.7) 4.9 (3.4)
   Median 3.5 4.5
   Range (min-max) 0.3–18.4 0.3–14.8
Distribution of pain, n (%)   
   Lower extremities 85 (100) 82 (100)
   Upper extremities 37 (44) 32 (39)
Baseline mean pain score   
   Mean (SD) 6.58 (1.58) 6.28 (1.47)
   Median 6.57 6.14
   Range (min-max) 3.71–10.00 3.57–9.71